Le Lézard
Classified in: Health
Subjects: SBS, MAT

Arizona Cannabis Cultivation & Production Lease Opportunity Available


PHOENIX, July 16, 2020 /PRNewswire/ -- iLAVA of Arizona owns 100% of a cultivation and processing license and is now requesting proposals for a financed operator with cultivation experience to enter one of America's top cannabis markets. Our ideal partner must be focused on quality control, compliance, and has experience designing and building out cannabis cultivation operations. The Arizona medical marijuana program and upcoming adult use initiative do not limit cultivation canopy size or limit plant count. Arizona's population is over 7.2 million as of 2019.

Over 190,000 lbs. of medical marijuana is sold per year in the Arizona cannabis market. In May 2020, cannabis sales in Arizona's medical dispensaries reached $93 million, growing seven percent from April. There are currently over 245,000 registered medical marijuana patients in Arizona and patient cards are valid for 2 years.

The iLAVA management team opened The Downtown Dispensary in 2013 which has won Best of Tucson® in 2015, 2016, 2017, and 2019. The iLAVA team currently operates 2 dispensaries and an industrial medical marijuana cultivation/production facility with 120+ employees in Tucson. iLAVA products are also distributed in 80+ dispensaries statewide including the bestselling topical in Arizona, iLAVA Touch, in addition to our vape cartridges & extracts. Arizona currently has 126 operating dispensaries statewide.

The iLAVA distribution network and the product expertise of our retail staff will be available to our potential partners. This opportunity includes cultivation and can include marijuana product manufacturing & distribution depending on negotiated deal terms.

Due to Arizona's medical marijuana laws and our internal practices, any qualified individuals must be able to pass a criminal background check and provide proof of funding upon request.

This opportunity is being listed by the iLAVA management team (Moe Asnani & Chip Boyden) and not by a broker or third party.

Interested parties who want to enter the Arizona market can email their proposals to info@ilava.com. Visit ilava.com to learn more about us.

Media contact:
Natalie Beckley
243661@email4pr.com 
602-621-0648

SOURCE iLAVA


These press releases may also interest you

at 02:16
Immunovia invites to a teleconference (in English) for investors, analysts and media on Thursday, August 20th, 2020 at 16:30 CET. Immunovia will publish the company's interim report on August 20th, 2020 at 16:00 CET. Mats Grahn, CEO will present...

at 02:05
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the initiation of its Phase II programme evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry...

at 02:00
Utilizing Bluetooth Low Energy ("BLE") technology, Mobile Programming LLC has developed a COVID-19 Contact Tracing Application to help organizations get back to work safely, while addressing COVID-19 health and safety concerns. Because COVID-19 is...

at 01:36
"In June we successfully closed a $90m U.S. IPO on NASDAQ, which including the greenshoe that was exercised in July, resulted in gross proceeds of $97m in total. This successful and pioneering transaction, which was the first time a Swedish life...

at 01:21
Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for ?20.3M in cash at ?2.80 per share in an off-market transaction. Following the closing of the control transaction...

at 01:10
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental Biologics License Application (sBLA) for a new self-administration option for...



News published on 16 july 2020 at 09:39 and distributed by: